Drug combinations with proteasome inhibitors in antitumor therapy
L Gatti, V Zuco, N Zaffaroni… - Current pharmaceutical …, 2013 - ingentaconnect.com
The proteasome has been regarded as a major target for antitumor therapy in selected
tumor types (ie, multiple myeloma). Available evidence suggests that targeting the
proteasome with selective compounds can represent an excellent approach for modulating
the response to antitumor agents including both conventional cytotoxic agents and target-
specific agents. In fact, promising drug interaction data showing synergistic effects have
been reported in cellular studies, both in multiple myeloma and in solid tumors. The …
tumor types (ie, multiple myeloma). Available evidence suggests that targeting the
proteasome with selective compounds can represent an excellent approach for modulating
the response to antitumor agents including both conventional cytotoxic agents and target-
specific agents. In fact, promising drug interaction data showing synergistic effects have
been reported in cellular studies, both in multiple myeloma and in solid tumors. The …
以上显示的是最相近的搜索结果。 查看全部搜索结果